UPCC 05418: A Multicenter Double-Blind Randomized Placebo-Controlled Phase III Study of Idasanutlin an MDM2 Antagonist with Cytarabine Versus Cytarabine Plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

UPCC 05418: A Multicenter  Double-Blind  Randomized  Placebo-Controlled  Phase III Study of Idasanutlin  an MDM2 Antagonist  with Cytarabine Versus Cytarabine Plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Brief description of study

The purpose of this study is to compare the effects, good or bad, of idasanutlin plus cytarabine (chemotherapy) versus placebo (an inactive substance that looks like idasanutlin) plus cytarabine on patients with relapsed or refractory Acute Myeloid Leukemia (AML) to find out which is better.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    ['Leukemia, Myeloid, Acute']
  • Age: - 99 Years
  • Gender: All
Updated on 30 Jan 2020. Study ID: 829461

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center